newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax